Akums Launches Novel Formulations For Patients With Gastrointestinal Disorders

New Delhi: Akums Drugs & Pharmaceuticals Ltd on Monday announced that it has launched Rabeprazole + Levosulpiride SR Capsules. Approved by the Drug Controller General of India (DCGI), the company claims this new formulation aims to enhance relief for patients suffering from gastrointestinal tract (GIT) disorders.

GERD, or gastro-oesophageal reflux disease, is a debilitating condition characterised by the reflux of stomach contents into the oesophagus, leading to troublesome symptoms and potential complications. With GERD often dubbed as chronic acid reflux, its prolonged presence not only impacts the quality of life but also poses risks of serious health complications, including stomach and esophageal cancer.

“Rabeprazole sodium, a potent antisecretory compound, selectively inhibits gastric acid secretion by targeting the H+ and K+ ATPase at the surface of gastric parietal cells. It has demonstrated efficacy in treating gastric and duodenal ulcers, as well as GERD. Complementing rabeprazole, Levosulpiride, the levo-enantiomer of sulpiride, exhibits significant central antidopaminergic activity and antiemetic effects,” the company said in a statement.

Its peripheral anti-dopaminergic action modulates the motor activity of the upper digestive tract, making it valuable in gastro-enterology, it claimed.

“We are excited to introduce a solution for patients suffering from GERD and related gastrointestinal disorders. GERD diagnosis and treatment rely on symptom management and acid suppression therapies. Our Rabeprazole + Levosulpiride SR Capsules aim to offer an effective remedy, ease symptoms, enhance gastrointestinal function, and boost patients’ overall well-being. Levosulpiride offers rapid relief and better healing outcomes with fewer side effects, elevating the overall treatment experience,” Arushi Jain, Director, Akums Drugs & Pharmaceuticals Ltd. said in a statement.

Each hard gelatin capsule contains Rabeprazole Sodium IP 40 mg (as enteric-coated form) and Levosulpiride 75 mg (as uncoated sustained-release form). The recommended dosage is one capsule once daily or as directed by a physician.

Related Posts

Sun Pharma recalls over 1900 bottles of epilepsy drug in US

According to the US FDA’s latest enforcement report, the recall was initiated after black spots were found on the tablets due to burnt excipient used for manufacturing. New Delhi: Sun…

Delhi Police Bust Illegal Network Smuggling Counterfeit and Unauthorised Anti-Cancer Medicines in Delhi-NCR

New Delhi: The Delhi Police Crime Branch has busted an alleged illegal network involved in the smuggling, adulteration and distribution of counterfeit and unauthorised anti-cancer and other life-saving medicines in the…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Sun Pharma recalls over 1900 bottles of epilepsy drug in US

Sun Pharma recalls over 1900 bottles of epilepsy drug in US

Delhi Police Bust Illegal Network Smuggling Counterfeit and Unauthorised Anti-Cancer Medicines in Delhi-NCR

Delhi Police Bust Illegal Network Smuggling Counterfeit and Unauthorised Anti-Cancer Medicines in Delhi-NCR

Pharmacy worker arrested for illegally supplying prescription drugs, ₹4.8 lakh worth of drugs seized

Pharmacy worker arrested for illegally supplying prescription drugs, ₹4.8 lakh worth of drugs seized

Meiji Seika to push new vaccine with SII in India

Meiji Seika to push new vaccine with SII in India

DGFT automates EO extension process to ease compliance for pharma exporters

DGFT automates EO extension process to ease compliance for pharma exporters

Udan vs Udaan: Delhi court restrains pharmaceutical firm from using ‘Udaan’ mark

Udan vs Udaan: Delhi court restrains pharmaceutical firm from using ‘Udaan’ mark